Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of CCR4 CAR T cells in relapsed or refractory CCR4-positive T-cell malignancies
jRCT2033260502Phase 1Not yet recruiting
- Sponsor
- ARC Therapies
- Start
- Jan 2027
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CCR4 CAR T cells in T-cell lymphoma and adult T-cell leukemia-lymphoma (ATLL), sponsored by ARC Therapies. Primary endpoint: Dose-limiting toxicity rate. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
CCR4 CAR T cells
03
Conditions
T-cell lymphomaadult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2033260502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260502.